Joan W. Miller, M.D.
Henry Willard Williams Professor of Ophthalmology
Chair, Department of Ophthalmology
Chief of Ophthalmology
- AMD Center of Excellence
- Angiogenesis Laboratory
- Diabetic Eye Disease Center of Excellence
- Glaucoma Center of Excellence
- Ocular Genomics Institute
- Ocular Regenerative Medicine Institute
Dr. Miller’s clinical and research interests focus on retinal disorders, including age related macular degeneration (AMD), diabetic eye disease, and macular telangiectasia (MacTel). She and her colleagues at Mass. Eye and Ear pioneered the development of photodynamic therapy (PDT) using verteporfin (Visudyne®), the first pharmacologic therapy for AMD. Dr. Miller also identified the role of vascular endothelial growth factor (VEGF) in ocular neovascularization, forming the scientific basis of current antiangiogenic therapies for intraocular vascular diseases (including neovascular AMD and diabetic eye disease). Dr. Miller continues investigations to elucidate the pathophysiology of vision loss and improve therapies for retinal diseases.
Neuroprotective therapies for retinal disease: Dr. Miller studies the mechanisms of photoreceptor and retinal pigment epithelium (RPE) cell death with the goal of developing effective combination neuroprotective therapies.
Genetics of AMD: In collaboration with Dr. Margaret DeAngelis of University of Utah, Dr. Miller is identifying novel loci associated with AMD and genetic differences in AMD subtypes using sibling-correlation and genome-wide association studies.
Dietary interventions for AMD: A co-investigator in the Age-Related Eye Disease Study 2 (AREDS2), Dr. Miller studied the effects of dietary constituents in preventing AMD progression. In the laboratory, she examines the anti-inflammatory and antiangiogenic effects of fatty acid metabolites in animal models of AMD.
The MacTel Project: Dr. Miller is an investigator in a collaborative research effort to identify the causes and appropriate treatments for this idiopathic condition.
1. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 Sep; 145 (3) :574-84. PubMed PMID:7521577; PubMed Central PMCID: PMC1890317.
2. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte TJ, Haimovici R, Gragoudas ES. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995 Jun; 113 (6) :810-8. PubMed PMID:7540388.
3. [No Authors Listed*] Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct; 117 (10) :1329-45. PubMed PMID:10532441. (*member of the investigative team cited in the appendix of the manuscript)
4. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar; 120 (3) :338-46. PubMed PMID:11879138.
5. Murakami Y, Matsumoto H, Roh M, Suzuki J, Hisatomi T, Ikeda Y, Miller JW, Vavvas DG. Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14598-603. doi: 10.1073/pnas.1206937109. Epub 2012 Aug 20. PubMed PMID: 22908283; PubMed Central PMCID: PMC3437885
1980: S.B., Life Sciences, Massachusetts Institute of Technology
1981–1985: M.D., cum laude, Harvard Medical School
1985–1986: Internship, Medicine, Newton-Wellesley Hospital
1986–1989: Residency, Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary
1989–1991: Fellowship, Vitreoretinal Surgery, Massachusetts Eye and Ear Infirmary
1989–1991: Research Fellowship, Massachusetts Eye and Ear Infirmary
Professional Memberships (select)
1984: Massachusetts Medical Society
1987: American Medical Association
1989: Association for Research in Vision and Ophthalmology, Member, ARVO Foundation Board of Governors, 2013–2016
1991: American Board of Ophthalmology, Examiner, 2007–
1992: American Academy of Ophthalmology, Retina Panel, Preferred Practice Patterns, 2002–2005
1992: American Association for the Advancement of Science
1993: Research to Prevent Blindness
1994: New England Ophthalmological Society, President, 2013–2014
1995: Retina Society
1995: Macula Society
1998: Club Jules Gonin
2002: Alcon Research Institute
2007: Women in Retina
2007: Women in Ophthalmology (Nominating Committee, 2007–)
2008: American Ophthalmological Society
2009: Women in Eye and Vision Research (2009– Leadership Committee)
2012: Heed Ophthalmic Foundation (2012– Board of Directors)
2013: Academia Ophthalmologica Internationalis (2013– Chair LXVIII)
1999: Rosenthal Award, Macula Society
2002: Retina Research Award, Club Jules Gonin
2006: ARVO/Pfizer Award
2009: J. Donald Gass Medal, Macula Society
2010: Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty, Harvard Medical School
2011: Paul Henkind Memorial Award, Macula Society
2012: Edward Jackson Memorial Lectureship, American Academy of Ophthalmology 2013: Honoree, ARVO Foundation for Eye Research
2000: "Best of What's New" Award (Visudyne), Popular Science
2000: "Top Products of 2000" Award (Visudyne), Business Week
2012: Pinnacle Award for Achievement in the Professions, Greater Boston Chamber of Commerce
2012: Boston's Best Doctors, Boston Magazine
Editorial Roles (select)
2005–2013: Editorial Board, JAMA Ophthalmology (formerly Archives of Ophthalmology)
2013: Editorial Board Ophthalmology
2005: Co-Director, Residents Course (biennial), Harvard Medical School
2010: Co-Director, Department of Ophthalmology Biennial Symposium on Age-Related Macular Degeneration (biennial)
Harvard Medical School
2012–2012: Program Co-Director, Retina Subspecialty Day, American Academy of Ophthalmology (In conjunction with the American Society of Retina Specialists, the Macula Society, the Retina Society, and Club Jules Gonin)
Other Professional Roles/Advisory Boards
2011: Consultant, Alcon Laboratories, Inc.
2012: Consultant, KalVista Pharmaceuticals, Ltd.
2013: Consultant, Regeneron Pharmaceuticals, Inc.
2013: Consultant, ISIS Pharmaceuticals, Inc.
2013: Consultant, Imagen Biotech, Inc.
2013–present: Scientific Advisory Board, ONL Therapeutics, LLC
1. Miller JW, Young LHY, Gragoudas ES, inventors; Massachusetts Eye and Ear Infirmary, assignee. Angiographic method using green porphyrins in primate eyes. United States Patent US 5,707,986. January 13, 1998.
2. Levy J, Miller JW, Gragoudas ES, Hasan T, Schmidt-Erfurth U, inventors; The General Hospital Corporation, Quadra Logic Technologies, Inc., Massachusetts Eye and Ear Infirmary, assignees. Use of green porphyrins to treat neovasculature in the eye. United States Patent US 5,798,349. August 25, 1998.
3. Miller JW, Gragoudas ES, inventors; Massachusetts Eye and Ear Infirmary, assignee. Use of green porphyrins to treat neovasculature in the eye. United States Patent US 6,225,303. May 1, 2001.
4. Miller JW, Gragoudas ES, inventors; Massachusetts Eye and Ear Infirmary, assignee. Use of green porphyrins to treat neovasculature in the eye. United States Patent US 6,610,679. August 26, 2003.
5. Miller JW, Gragoudas ES, Renno RZ, inventors; Massachusetts Eye and Ear Infirmary, assignee. Methods and compositions for treating conditions of the eye. United States Patent US 7,125,542. October 24, 2006.
6. Iliaki E, Adamis AP, Miller JW, Gragoudas ES, inventors; Massachusetts Eye and Ear Infirmary, assignee. Treatment of ocular disorders. United States Patent US 7,419,666. September 2, 2008.
7. Adamis AP, Miller JW, Gragoudas ES, Mescher MJ, Dube CE, Borenstein JT, Weinstein MG, Miller RA, Hansberry ML; Massachusetts Eye and Ear Infirmary, The Charles Stark Draper Laboratory, Inc., assignees. Implantable Drug Delivery Device and Use Thereof. United States Patent US 7,563,255. July 21, 2009.
8. Gragoudas ES, Poulaki V, Miller JW, inventors; Massachusetts Eye and Ear Infirmary, assignee. Methods and compositions for treating conditions of the eye. United States Patent US 7,803,375.
9. Zacks D, Miller JW, inventors; Massachusetts Eye and Ear Infirmary, assignee. Methods for preserving the viability of photoreceptor cells by anti-FAS-ligand/anti-FAS-receptor antibodies. United States Patent US 7,811,832. October 12, 2010.